A retrospective, nationwide study to evaluate the efficacy and safety of salvage sofosbuvir/velpatasvir/voxilaprev for HCV NS5A-inhibitor experienced patients with difficult to cure characteristics
Latest Information Update: 08 Sep 2020
At a glance
- Drugs Sofosbuvir/velpatasvir/voxilaprevir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 08 Sep 2020 New trial record
- 05 Sep 2020 Results published in the Clinical Infectious Diseases